A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 103, Issue 39, 2006, Pages 14566-14571

  Muschiol, Sandra ^a,b   Bailey, Leslie ^c   Gylfe, Åsa ^c   Sundin, Charlotte ^d   Hultenby, Kjell ^b   Bergström, Sven ^c   Elofsson, Mikael ^c   Wolf Watz, Hans ^c   Normark, Staffan ^a,b   Henriques Normark, Birgitta ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d Innate Pharmaceuticals AB   (Sweden)

Author keywords

Type III secretion system

Indexed keywords

INP 0400; PROTEIN 14 3 3; PROTEIN 14 3 3BETA; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL VIRULENCE; CELL INCLUSION; CELL MEMBRANE; CELL ULTRASTRUCTURE; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; CYTOSOL; DOSE RESPONSE; DRUG MECHANISM; ELEMENTARY BODY; HOST CELL; INCLUSION MEMBRANE; LIFE CYCLE; MEMBRANE FUSION; MEMBRANE VESICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION; RETICULATE BODY; TREATMENT OUTCOME; TYPE III SECRETION SYSTEM; YERSINIA PSEUDOTUBERCULOSIS;

14-3-3 PROTEINS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CELL DIFFERENTIATION; CELL MEMBRANE; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DOSE-RESPONSE RELATIONSHIP, DRUG; INCLUSION BODIES; MEMBRANE FUSION; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT;

CHLAMYDIA TRACHOMATIS; MAMMALIA; YERSINIA PSEUDOTUBERCULOSIS;

EID: 33749259792     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0606412103     Document Type: Article

References (26)

1. Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ (2005) Science 310:670-674.
2. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M (2003) Chem Biol 10:241-249.
3. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M (2005) Infect Immun 73:3104-3114.
4. Schachter J (1999) in Chlamydia: Intracellular Biology, Pathogenesis, and Immunity, ed Stephens RS (Am Soc Microbiol, Washington, DC), pp 139-169.
5. AbdelRahman YM, Belland RJ (2005) FEMS Microbiol Rev 29:949-959.
6. Hackstadt T, Rockey DD, Heinzen RA, Scidmore MA (1996) EMBO J 15:964-977.
7. Beatty WL (2006) J Cell Sci 119:350-359.
8. Hsia RC, Pannekoek Y, Ingerowski E, Bavoil PM (1997) Mol Microbiol 25:351-359.
9. Hueck CJ (1998) Microbiol Mol Biol Rev 62:379-433.
10. Clifton DR, Fields KA, Grieshaber SS, Dooley CA, Fischer ER, Mead DJ, Carabeo RA, Hackstadt T (2004) Proc Natl Acad Sci USA 101:10166-10171.
11. Rockey DD, Scidmore MA, Bannantine JP, Brown WJ (2002) Microbes Infect 4:333-340.
12. Scidmore MA, Hackstadt T (2001) Mol Microbiol 39:1638-1650.
13. Hackstadt T, Scidmore-Carlson MA, Shaw EI, Fischer ER (1999) Cell Microbiol 1:119-130.
14. Fling SP, Sutherland RA, Steele LN, Hess B, D'Orazio SE, Maisonneuve J, Lampe MF, Probst P, Starnbach MN (2001) Proc Natl Acad Sci USA 30:1160-1165.
15. Fields KA, Hackstadt T (2000) Mol Microbiol 38:1048-1060.
16. Subtil A, Delevoye C, Balana ME, Tastevin L, Perrinet S, Dautry-Varsat A (2005) Mol Microbiol 56:1636-1647.
17. Stenner-Liewen F, Liewen H, Zapata JM, Pawlowski K, Godzik A, Reed JC (2002) J Biol Chem 277:9633-9636.
18. Zhong G, Fan P, Ji H, Dong F, Huang Y (2001) J Exp Med 193:935-942.
19. Scidmore-Carlson MA, Shaw EI, Dooley CA, Fischer ER, Hackstadt T (1999) Mol Microbiol 33:753-765.
20. Ho TD, Starnbach MN (2005) Infect Immun 73:905-911.
21. Suchland RJ, Rockey DD, Bannantine JP, Stamm WE (2000) Infect Immun 68:360-361.
22. Rockey DD, Viratyosin W, Bannantine JP, Suchland RJ, Stamm WE (2002) Microbiology 148:2497-2505.
23. Hackstadt T, Fischer ER, Scidmore MA, Rockey DD, Heinzen RA (1997) Trends Microbiol 5:305-306.
24. Wylie JL, Hatch GM, McClarty G (1997) J Bacteriol 179:7233-7242.
25. Newhall WJ (1988) in Microbiology of Chlamydia, ed Barren AL (CRC, Boca Raton, FL), pp 47-70.
26. Kenny B, DeVinney R, Stein M, Reinscheid DJ, Frey EA, Finlay BB (1997) Cell 91:511-520.